| Q42206991 | A deficiency in nucleoside salvage impairs murine lymphocyte development, homeostasis, and survival |
| Q38838837 | A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation |
| Q33849871 | A(2A) adenosine receptors in human peripheral blood cells |
| Q37994174 | A2 adenosine receptors and vascular pathologies |
| Q88866833 | A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression |
| Q35016529 | A2A adenosine receptor protects tumors from antitumor T cells. |
| Q35981065 | A2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis |
| Q36007662 | A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli |
| Q30440525 | A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. |
| Q36870179 | ADORA2A polymorphism predisposes children to encephalopathy with febrile status epilepticus |
| Q59341050 | ATP and Its Metabolite Adenosine as Regulators of Dendritic Cell Activity |
| Q35847438 | Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo |
| Q64241193 | Adenosine A2A Receptor Stimulation Inhibits TCR-Induced Notch1 Activation in CD8+T-Cells |
| Q33828033 | Adenosine A2A receptor activation and macrophage-mediated experimental glomerulonephritis |
| Q36879416 | Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. |
| Q34017174 | Adenosine A2A receptor activation protects CD4+ T lymphocytes against activation-induced cell death. |
| Q30423298 | Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment |
| Q36496998 | Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells |
| Q28250207 | Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment |
| Q40657274 | Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia |
| Q39004042 | Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases |
| Q37864112 | Adenosine and blood platelets |
| Q40729772 | Adenosine and lymphocyte regulation |
| Q36821572 | Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? |
| Q28343421 | Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling |
| Q29615344 | Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression |
| Q35085245 | Adenosine in fibrosis. |
| Q36174251 | Adenosine in inflammatory joint diseases. |
| Q37650141 | Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model |
| Q39793259 | Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway |
| Q34576595 | Adenosine metabolism and murine strain-specific IL-4-induced inflammation, emphysema, and fibrosis |
| Q38936385 | Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression. |
| Q24653697 | Adenosine receptors and asthma. |
| Q37565200 | Adenosine receptors and cancer. |
| Q47690581 | Adenosine receptors differentially regulate type 2 cytokine production by IL-33-activated bone marrow cells, ILC2s, and macrophages |
| Q43279099 | Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling |
| Q38358000 | Adenosine signalling in diabetes mellitus--pathophysiology and therapeutic considerations |
| Q36751593 | Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells: involvement of protein kinase A isozyme I (PKA I). |
| Q35566772 | Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells |
| Q90704170 | Adenosinergic signaling as a target for natural killer cell immunotherapy |
| Q36528787 | Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients |
| Q45362664 | Altered phenotype of regulatory T cells associated with lack of human immunodeficiency virus (HIV)-1-specific suppressive function. |
| Q37131959 | Anti-inflammatory effects of inosine in allergic lung inflammation in mice: evidence for the participation of adenosine A2A and A 3 receptors |
| Q33403252 | Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency |
| Q33892260 | CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. |
| Q35814795 | CD39 Expression Identifies Terminally Exhausted CD8+ T Cells |
| Q33959186 | CD39/adenosine pathway is involved in AIDS progression |
| Q44786390 | CD4(+)CD25 (+)CD127 (low/-) T cells: a more specific Treg population in human peripheral blood |
| Q38063958 | CD73 and adenosine generation in the creation of regulatory microenvironments. |
| Q27315065 | CD73 expression is dynamically regulated in the germinal center and bone marrow plasma cells are diminished in its absence |
| Q33533705 | CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression |
| Q94464383 | CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers |
| Q50236908 | Caffeine affects CD8+ lymphocyte apoptosis and migration differently in naïve and familiar individuals following moderate intensity exercise. |
| Q93088181 | Can Allosteric Receptor-Protein Interactions in Receptor Complexes Be a Molecular Mechanism Involved in Cancer Immune Therapy? |
| Q93504518 | Cancer Immunology & Immunotherapy 2008: From Discovery to Development to Drug |
| Q38737924 | Cancer Immunotherapy: Whence and Whither |
| Q28066199 | Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy |
| Q64996165 | Connection between γδ T-cell- and Adenosine- Mediated Immune Regulation in the Pathogenesis of Experimental Autoimmune Uveitis. |
| Q37257326 | Correlation of low CD73 expression on synovial lymphocytes with reduced adenosine generation and higher disease severity in juvenile idiopathic arthritis. |
| Q54986388 | Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors. |
| Q35067400 | Deficits in endogenous adenosine formation by ecto-5'-nucleotidase/CD73 impair neuromuscular transmission and immune competence in experimental autoimmune myasthenia gravis |
| Q30423015 | Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury |
| Q28572795 | Diabetes-induced decrease of adenosine kinase expression impairs the proliferation potential of diabetic rat T lymphocytes |
| Q26774590 | Disrupted regulatory T cell homeostasis in inflammatory bowel diseases |
| Q64274419 | Dysregulation of Adenosinergic Signaling in Systemic and Organ-Specific Autoimmunity |
| Q34462015 | Ecto-5'-nucleotidase (CD73) attenuates allograft airway rejection through adenosine 2A receptor stimulation. |
| Q36350059 | Ectonucleotidases in solid organ and allogeneic hematopoietic cell transplantation |
| Q42046896 | Effect of low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils |
| Q48333043 | Enzymes as Immunotherapeutics. |
| Q48117133 | Evaluation of acetylcholinesterase and adenosine deaminase activities in brain and erythrocytes and proinflammatory cytokine levels in rats submitted to neonatal hypoxia-ischemia model |
| Q41928490 | Expression of CD39 mRNA is altered in the peripheral blood of patients with allergic asthma |
| Q40730004 | Extracellular NAD and ATP: Partners in immune cell modulation. |
| Q33878542 | Extracellular adenosine-mediated modulation of regulatory T cells |
| Q39396959 | Fall in oxygen tension of culture medium stimulates the adenosinergic signalling of a human T cell line. |
| Q36666221 | Forskolin-inducible cAMP pathway negatively regulates T-cell proliferation by uncoupling the interleukin-2 receptor complex |
| Q90242301 | Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients |
| Q40729839 | From "Hellstrom Paradox" to anti-adenosinergic cancer immunotherapy |
| Q36174658 | Fructose 1,6-bisphosphate, a high-energy intermediate of glycolysis, attenuates experimental arthritis by activating anti-inflammatory adenosinergic pathway |
| Q42010326 | Functional expression of the P2Y14 receptor in murine T-lymphocytes |
| Q28348047 | Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice |
| Q55432885 | High level expression of A2ARs is required for the enhancing function, but not for the inhibiting function, of γδ T cells in the autoimmune responses of EAU. |
| Q35090797 | Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists |
| Q53371221 | Human CD39+ Treg Cells Express Th17-Associated Surface Markers and Suppress IL-17 via a Stat3-Dependent Mechanism. |
| Q41849280 | Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness |
| Q37729712 | Hypoxia induces T-cell apoptosis by inhibiting chemokine C receptor 7 expression: the role of adenosine receptor A(2). |
| Q36417929 | Hypoxia-Inducible Factor-2α Limits Natural Killer T Cell Cytotoxicity in Renal Ischemia/Reperfusion Injury |
| Q38728524 | Immune Alterations in CD8(+) T Cells Are Associated with Neuronal C-C and C-X-C Chemokine Receptor Regulation Through Adenosine A2A Receptor Signaling in a BTBR T(+) Itpr3(tf)/J Autistic Mouse Model. |
| Q56890107 | Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options |
| Q30426800 | Immunological alterations mediated by adenosine during host-microbial interactions |
| Q58802811 | Immunometabolism in cancer at a glance |
| Q37231003 | In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression |
| Q37390515 | Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer |
| Q37287000 | Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action |
| Q36233927 | Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma |
| Q38685844 | Interaction between saliva's adenosine and tick parasitism: effects on feeding and reproduction. |
| Q63977060 | Invited Lectures : Overviews Purinergic signalling: past, present and future |
| Q30437433 | Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-kappaB in A(2A) adenosine receptor induction |
| Q39197674 | Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment |
| Q28511939 | Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction |
| Q30433245 | Much Ado about Adenosine: Adenosine Synthesis and Function in Regulatory T Cell Biology |
| Q38636569 | Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy |
| Q40722338 | Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade |
| Q89881655 | On the mechanism of anti-CD39 immune checkpoint therapy |
| Q92650554 | Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro |
| Q46272404 | Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. |
| Q39281335 | Phenotypic and functional characteristics of CD39high human regulatory B cells (Breg). |
| Q38880404 | Phenotypic switch of CD8(+) T cells reactivated under hypoxia toward IL-10 secreting, poorly proliferative effector cells |
| Q37729535 | Pleural fluid from tuberculous pleurisy inhibits the functions of T cells and the differentiation of Th1 cells via immunosuppressive factors |
| Q64118859 | Polyphosphate as a Target for Interference With Inflammation and Thrombosis |
| Q35553464 | Possible targeting of G protein coupled receptors to manipulate inflammation in vivo using synthetic and natural ligands |
| Q36923670 | Purinergic Signaling and the Immune Response in Sepsis: A Review |
| Q36056842 | Purinergic Signaling as a Regulator of Th17 Cell Plasticity |
| Q38263455 | Purinergic signalling and immune cells |
| Q26823216 | Regulation generation: the suppressive functions of human regulatory T cells |
| Q52715799 | Regulatory T Cells As Potential Targets for HIV Cure Research. |
| Q34711777 | Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection |
| Q26745537 | Regulatory T-Cell-Mediated Suppression of Conventional T-Cells and Dendritic Cells by Different cAMP Intracellular Pathways |
| Q39157106 | Role of ATP as a Key Signaling Molecule Mediating Radiation-Induced Biological Effects |
| Q38957379 | Role of Metabolism in the Immunobiology of Regulatory T Cells |
| Q34277485 | Roles of the adenosine receptor and CD73 in the regulatory effect of γδ T cells |
| Q36750277 | SKCa Channels Blockage Increases the Expression of Adenosine A2A Receptor in Jurkat Human T Cells |
| Q90655148 | Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers |
| Q33163021 | Search for adenosine A2A spare receptors on peripheral human lymphocytes |
| Q35042656 | Study of A(2A) adenosine receptor gene deficient mice reveals that adenosine analogue CGS 21680 possesses no A(2A) receptor-unrelated lymphotoxicity |
| Q50043938 | T Cell Exhaustion Signatures Vary with Tumor Type and are Severe in Glioblastoma |
| Q35199844 | T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus |
| Q60921609 | Targeting Adenosine Receptor Signaling in Cancer Immunotherapy |
| Q93062525 | Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function |
| Q36620552 | Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer |
| Q30434114 | The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells |
| Q30426440 | The A2B adenosine receptor promotes Th17 differentiation via stimulation of dendritic cell IL-6 |
| Q48191363 | The Hypoxia-Adenosine Link during Intestinal Inflammation. |
| Q37524827 | The adenosinergic immunomodulatory drugs |
| Q37535392 | The antihypoxia-adenosinergic pathogenesis as a result of collateral damage by overactive immune cells |
| Q36075960 | The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. |
| Q39397379 | The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27 |
| Q34700443 | The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection |
| Q36357953 | The promise of immune cell therapy for acute kidney injury |
| Q59341217 | Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells |
| Q92282117 | Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response |
| Q26862220 | Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity |
| Q48284423 | Unfolding Role of a Danger Molecule Adenosine Signaling in Modulation of Microbial Infection and Host Cell Response. |
| Q38785475 | Unlocking the Potential of Purinergic Signaling in Transplantation |